Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

S&P Dow Jones uses “float” – the value of shares that aren’t held by insiders and that therefore trade frequently and are ...

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan- ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...